Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Retained Earnings (2021 - 2025)

Caribou Biosciences (CRBU) has disclosed Retained Earnings for 5 consecutive years, with $103000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 59.61% to $103000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $103000.0 through Dec 2025, down 59.61% year-over-year, with the annual reading at $103000.0 for FY2025, 59.61% down from the prior year.
  • Retained Earnings for Q4 2025 was $103000.0 at Caribou Biosciences, up from -$570.0 million in the prior quarter.
  • The five-year high for Retained Earnings was $789000.0 in Q3 2024, with the low at -$570.0 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$146.3 million, with a median of -$58.3 million recorded in 2021.
  • The sharpest move saw Retained Earnings skyrocketed 180.43% in 2024, then plummeted 169962.7% in 2025.
  • Over 5 years, Retained Earnings stood at -$135000.0 in 2021, then tumbled by 145985.19% to -$197.2 million in 2022, then plummeted by 51.76% to -$299.3 million in 2023, then skyrocketed by 100.09% to $255000.0 in 2024, then tumbled by 59.61% to $103000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $103000.0, -$570.0 million, and -$542.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.